Proxar – Finasteride 5 mg
Proxar is presented in the ORYVION catalog as a tablet formulation containing 5 mg of finasteride per tablet, supplied in containers of 50 tablets. Finasteride is an orally active inhibitor of type II 5-alpha-reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT).
Its pharmacological action reduces DHT concentrations in the blood and androgen-sensitive tissues. The established medical application of the 5 mg formulation is the treatment of benign prostatic hyperplasia in men with an enlarged prostate. By reducing DHT activity, finasteride can decrease prostate volume and improve associated urinary symptoms.
Product Specifications:
Commercial name: Proxar
Listed compound: Finasteride
Declared strength: 5 mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Finasteride can cause decreased libido, erectile dysfunction, and ejaculation disorders. Sexual symptoms persisting after discontinuation have been reported. It also lowers prostate-specific antigen (PSA), which can affect interpretation of prostate screening results. Exposure during pregnancy can harm the development of a male fetus; pregnant individuals should not handle crushed or broken tablets.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.